CapWealth Advisors LLC Sells 5,561 Shares of Merck & Co., Inc. (NYSE:MRK)

CapWealth Advisors LLC cut its stake in Merck & Co., Inc. (NYSE:MRKFree Report) by 2.5% in the first quarter, HoldingsChannel reports. The institutional investor owned 220,933 shares of the company’s stock after selling 5,561 shares during the quarter. Merck & Co., Inc. makes up about 3.3% of CapWealth Advisors LLC’s holdings, making the stock its 7th biggest holding. CapWealth Advisors LLC’s holdings in Merck & Co., Inc. were worth $29,152,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of MRK. Cross Staff Investments Inc grew its stake in Merck & Co., Inc. by 3.5% during the fourth quarter. Cross Staff Investments Inc now owns 6,710 shares of the company’s stock worth $732,000 after buying an additional 225 shares during the last quarter. PFW Advisors LLC acquired a new position in shares of Merck & Co., Inc. in the 1st quarter worth approximately $212,000. Dynamic Advisor Solutions LLC grew its position in Merck & Co., Inc. by 6.0% during the 1st quarter. Dynamic Advisor Solutions LLC now owns 77,833 shares of the company’s stock worth $10,270,000 after acquiring an additional 4,433 shares during the last quarter. Kennedy Investment Group increased its holdings in Merck & Co., Inc. by 16.0% during the 4th quarter. Kennedy Investment Group now owns 2,564 shares of the company’s stock valued at $280,000 after purchasing an additional 354 shares in the last quarter. Finally, Schear Investment Advisers LLC raised its position in Merck & Co., Inc. by 16.0% in the 4th quarter. Schear Investment Advisers LLC now owns 3,233 shares of the company’s stock valued at $352,000 after purchasing an additional 445 shares during the last quarter. 76.07% of the stock is owned by institutional investors and hedge funds.

Merck & Co., Inc. Trading Up 0.9 %

Shares of MRK stock traded up $1.09 during trading hours on Wednesday, reaching $127.13. The company had a trading volume of 643,813 shares, compared to its average volume of 8,396,154. Merck & Co., Inc. has a 1-year low of $99.14 and a 1-year high of $134.63. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.25 and a quick ratio of 0.99. The firm has a market cap of $322.00 billion, a price-to-earnings ratio of 140.09, a P/E/G ratio of 2.43 and a beta of 0.38. The company has a 50 day moving average of $128.99 and a 200 day moving average of $125.39.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last released its quarterly earnings data on Thursday, April 25th. The company reported $2.07 EPS for the quarter, beating analysts’ consensus estimates of $1.94 by $0.13. Merck & Co., Inc. had a return on equity of 14.05% and a net margin of 3.76%. The business had revenue of $15.78 billion during the quarter, compared to the consensus estimate of $15.21 billion. During the same quarter in the prior year, the company posted $1.40 earnings per share. The firm’s revenue was up 8.9% on a year-over-year basis. On average, equities research analysts anticipate that Merck & Co., Inc. will post 8.62 EPS for the current year.

Merck & Co., Inc. Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, July 8th. Investors of record on Monday, June 17th were paid a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a yield of 2.42%. The ex-dividend date of this dividend was Monday, June 17th. Merck & Co., Inc.’s payout ratio is 342.22%.

Analyst Ratings Changes

Several analysts have recently commented on MRK shares. Argus upgraded Merck & Co., Inc. to a “strong-buy” rating in a report on Wednesday, June 5th. Berenberg Bank increased their price objective on shares of Merck & Co., Inc. from $140.00 to $143.00 and gave the stock a “buy” rating in a report on Monday, April 8th. Wells Fargo & Company boosted their target price on shares of Merck & Co., Inc. from $130.00 to $135.00 and gave the stock an “equal weight” rating in a research note on Wednesday, March 27th. Cantor Fitzgerald reissued an “overweight” rating and set a $155.00 price target on shares of Merck & Co., Inc. in a research note on Tuesday, June 18th. Finally, Truist Financial upped their price objective on Merck & Co., Inc. from $142.00 to $143.00 and gave the stock a “buy” rating in a report on Friday, April 26th. One analyst has rated the stock with a sell rating, three have issued a hold rating, eight have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $133.00.

Get Our Latest Analysis on MRK

Merck & Co., Inc. Company Profile

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

Featured Articles

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKFree Report).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.